Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022;328:57–68. https://doi.org/10.1001/JAMA.2022.10233.

Article  CAS  PubMed  Google Scholar 

Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Prim. 2018;4:1–22. https://doi.org/10.1038/nrdp.2018.10.

Article  Google Scholar 

Scott AW. Ophthalmic manifestations of sickle cell disease. South Med J. 2016;109:542–8. https://doi.org/10.14423/SMJ.0000000000000525.

Article  PubMed  Google Scholar 

Goldberg MF. Natural history of untreated proliferative sickle retinopathy. Arch Ophthalmol. 1971;85:428–7. https://doi.org/10.1001/ARCHOPHT.1971.00990050430006.

Article  CAS  PubMed  Google Scholar 

Fox PD, Rupert Vessey SJ, Forshaw ML, Serjeant GR. Influence of genotype on the natural history of untreated proliferative sickle retinopathy—an angiographic study. Br J Ophthalmol. 1991;75:229–1. https://doi.org/10.1136/BJO.75.4.229.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdalla Elsayed MEA, Mura M, Al Dhibi H, et al. Sickle cell retinopathy: a focused review. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:1353–4. https://doi.org/10.1007/S00417-019-04294-2/FIGURES/3.

Article  CAS  Google Scholar 

Duan XJ, Lanzkron S, Linz MO, et al. Clinical and ophthalmic factors associated with the severity of sickle cell retinopathy. Am J Ophthalmol. 2018. https://doi.org/10.1016/j.ajo.2018.09.025.

Article  PubMed  Google Scholar 

Aleluia MM, Fonseca TCC, Souza RQ, et al. Comparative study of sickle cell anemia and hemoglobin SC disease: clinical characterization, laboratory biomarkers and genetic profiles. BMC Hematol. 2017. https://doi.org/10.1186/S12878-017-0087-7.

Article  PubMed  PubMed Central  Google Scholar 

Downes SM, Hambleton IR, Chuang EL, et al. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology. 2005;112:1869–5. https://doi.org/10.1016/J.OPHTHA.2005.05.026.

Article  PubMed  Google Scholar 

Penman AD, Serjeant GR. Recent advances in the management of proliferative diabetic retinopathy. Curr Opin Ophthalmol. 1992;3:379–8. https://doi.org/10.1097/ICU.0000000000000946.

Article  CAS  PubMed  Google Scholar 

Mishra K, Bajaj R, Scott AW. Variable practice patterns for management of sickle cell retinopathy. Ophthalmol Retina. 2021;5:715–7. https://doi.org/10.1016/J.ORET.2020.11.017.

Article  PubMed  Google Scholar 

Amissah-Arthur KN, Mensah E. The past, present and future management of sickle cell retinopathy within an African context. Eye. 2018;32:1304–14. https://doi.org/10.1038/s41433-018-0162-8.

Article  PubMed  PubMed Central  Google Scholar 

Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48. https://doi.org/10.1001/JAMA.2014.10517.

Article  PubMed  Google Scholar 

NIH Expert Panel Report (2014) Evidence-based management of sickle cell disease expert panel report, Guide to Recommendations

Martin GC, Albuisson E, Brousse V, et al. Paramacular temporal atrophy in sickle cell disease occurs early in childhood. Br J Ophthalmol. 2019;103:906–10. https://doi.org/10.1136/BJOPHTHALMOL-2018-312305.

Article  PubMed  Google Scholar 

Pahl DA, Green NS, Bhatia M, et al. Optical coherence tomography angiography and ultra-widefield fluorescein angiography for early detection of adolescent sickle retinopathy. Am J Ophthalmol. 2017;183:91–8. https://doi.org/10.1016/J.AJO.2017.08.010.

Article  PubMed  PubMed Central  Google Scholar 

Lim JI, Niec M, Sun J, Cao D. Longitudinal assessment of retinal thinning in adults with and without sickle cell retinopathy using spectral-domain optical coherence tomography. JAMA Ophthalmol. 2021;139:330–7. https://doi.org/10.1001/JAMAOPHTHALMOL.2020.6525.

Article  PubMed  PubMed Central  Google Scholar 

Badawy SM, Thompson AA, Penedo FJ, et al. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017;98:608–4. https://doi.org/10.1111/EJH.12878.

Article  CAS  PubMed  Google Scholar 

Cohen SB, Fletcher ME, Goldberg MF, Jednock NJ. Diagnosis and management of ocular complications of sickle hemoglobinopaties: part III. Ophthalmic Surg Lasers Imaging Retina. 1986;17:184–8. https://doi.org/10.3928/1542-8877-19860301-18.

Article  CAS  Google Scholar 

Rodrigues M, Kashiwabuchi F, Deshpande M, et al. Expression pattern of HIF-1α and VEGF supports circumferential application of scatter laser for proliferative sickle retinopathy. Invest Ophthalmol Vis Sci. 2016;57:6739–46. https://doi.org/10.1167/IOVS.16-19513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thangamathesvaran L, Scott AW (2022) Sickle cell retinopathy: an update on management. Retina Specialist. https://www.retina-specialist.com/article/sickle-cell-retinopathy-an-update-on-management. Accessed 29 Apr 2024.

Cai CX, Linz MO, Scott AW. Intravitreal bevacizumab for proliferative sickle retinopathy: a case series. J Vitreoretin Dis. 2018;2:32–8. https://doi.org/10.1177/2474126417738627.

Article  Google Scholar 

Scott AW (2021) Management challenges in sickle cell retinopathy. In: Review of Ophthalmology. https://www.reviewofophthalmology.com/article/management-challenges-in-sickle-cell-retinopathy. Accessed 29 Apr 2024

Babalola OE. Surgical approach to sickle cell retinopathy—retina today. BMJ Case Rep. 2010. https://doi.org/10.1136/BCR.11.2009.2441.

Article  PubMed  PubMed Central  Google Scholar 

Chen RWS, Flynn HW, Lee WH, et al. Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series. Am J Ophthalmol. 2014;157:870–5. https://doi.org/10.1016/J.AJO.2013.12.019.

Article  PubMed  Google Scholar 

Williamson TH, Rajput R, Laidlaw DAH, Mokete B. Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy. Eye (Lond). 2009;23:1314–20. https://doi.org/10.1038/EYE.2008.296.

Article  CAS  PubMed  Google Scholar 

Rohowetz LJ, Panneerselvam S, Williams BK, et al. Proliferative sickle cell retinopathy: outcomes of vitreoretinal surgery. Ophthalmol Retina. 2024. https://doi.org/10.1016/J.ORET.2024.01.023.

Article  PubMed  Google Scholar 

Nithianandan H, Sridhar J. Surgical and medical perioperative management of sickle cell retinopathy: a literature review. Int Ophthalmol Clin. 2020;60:77–87. https://doi.org/10.1097/IIO.0000000000000323.

Article  PubMed  PubMed Central  Google Scholar 

Oderinlo O, Umeh V, Hassan AO, et al. Technique and outcomes of vitreoretinal surgery for complications of proliferative sickle cell retinopathy. Niger J Ophthalmol. 2023;31:95. https://doi.org/10.4103/NJO.NJO_17_23.

Article  Google Scholar 

Moshiri A, Ha NK, Ko FS, Scott AW. Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment. Retin Cases Brief Rep. 2013;7:204–5. https://doi.org/10.1097/ICB.0B013E3182845D31.

Article  PubMed  Google Scholar 

Ahmed I, Pradeep T, Goldberg M, et al. Tele-ophthalmology screening for sickle cell retinopathy using ultra-widefield fundus photography. Invest Ophthalmol Vis Sci. 2021;62:1931.

Google Scholar 

Dinah C, Greystoke B, Mueller I, Talks J. Action on sickle cell retinopathy: the time is now. Eye. 2022;36(6):1138–9. https://doi.org/10.1038/s41433-021-01918-y.

Article  PubMed  PubMed Central  Google Scholar 

FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease FDA. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-patients-painful-complication-sickle-cell-disease. Accessed 24 Apr 2024

Tang MS, Shan H. Current state of gene therapy in sickle cell disease. Vox Sang. 2024.